Effectiveness of matured hop bitter acids for Parkinson's disease with mild cognitive decline: A randomized double blinded trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031190162

Enrollment

Registered

2020-01-01

Start date

2020-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease Parkinson's disease

Interventions

Matured hop bitter acids (35 mg) or placebo per day in 24 weeks. - Medical inquiry - UPDRS - PDQ-39 - Evaluation for cognitive function (MoCA-J) - Evaluation for cognitive function(Stroop test, Ver

cognitive function, inflammation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Parkinson's disease patients, treating or hospitalized in Juntendo University Hospital and 20-85 years old. 2) Patients whose score of MoCA-J is 10-25 3) Clinical stage: Hoehn and Yahr II-V 4) Patients who agreed with participating in this research with their own informed consent form after sufficient explanation

Exclusion criteria

Exclusion criteria: 1) Patients who cannot understand the aim of this research 2) Patients who have taken MAO-B inhibitor since a month before informed consent and who do not agree to refrain MAO-B inhibitor medication from informed consent to the end of joining study 3) Patients who regularly drink beer or beer taste beverage more than once a week 4) Smokers or heavy drinkers 5) Patients who receive brain stimulation medication 6) Patients who are not suitable for PET or MRI scan(for example, with pacemaker, with metal in body such as brain clips and bolts, with tattoos or with risk of arterial blood sampling (prone to bleeding and allergies to local anesthetics or anticoagulants)) 7) Patients who suffer from severe heart, kidney, liver or digestive diseases 8) Patients receiving cancer treatment 9) Patients who are, or are planning to be pregnant 10) Patients who are judged as unsuitable by doctor for other reasons

Design outcomes

Primary

Measure	Time frame
Cognitive function (MoCA-J, Stroop test, Verbal fluency test, Visual paired associates test)	—

Secondary

Measure	Time frame
PET, MRI, Questionnaires for QOL (PDQ-39, POMS2), UPDRS, Subjective questionnaire (Metamemory in Adulthood questionnaire, Pittsburgh Sleep Quality Index)	—

Contacts

Public ContactTaku Hatano

Juntendo University Hospital

thatano@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026